ERBB2 and cancer: Patient recruitment is currently underway for CT-0508 (anti-HER2 CAR-Ms), a multicentre Phase I clinical trial targeting patients with recurrent or metastatic solid tumors with HER2 overexpression whose cancer is not approved for HER2-targeted therapy or is not responding to treatment (NCT04660929).